BioSpace News Archive

CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership team.

Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study.

Carisma Therapeutics Inc. today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT-0525.

Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week.

BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024.

The global industrial microbiology market size was valued at USD 13.67 billion in 2023 and it is expanding at a CAGR of 5.57% from 2024 to 2033, to reach around USD 23.52 billion by 2033.

Orlance, a pioneering Seattle-based biotech company, is thrilled to announce a new development project with esteemed partner Product Creation Studio, a leader in innovative engineering and design services.

Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk score can accurately predict the benefit of adding androgen deprivation therapy to radiation therapy in men with localized prostate cancer.